Interestingly, several cardiovascular diseases as well as obesity and type 2 diabetes-related disorders, clinical conditions often interrelated as co-morbidities, converge in displaying increased GRK2 levels, pointing at the inhibition of GRK2 as an attractive therapeutic target. This evidence concerns the gene GRK2 and Obesity.